Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ENLV Enlivex Therapeutics Ltd

Price (delayed)

$0.93

Market cap

$22.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$1.63M

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib ...

Highlights
Enlivex Therapeutics's EPS has soared by 53% YoY and by 10% from the previous quarter
Enlivex Therapeutics's net income has increased by 45% YoY and by 4.6% from the previous quarter
ENLV's equity is down by 23% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of ENLV
Market
Shares outstanding
23.85M
Market cap
$22.18M
Enterprise value
$1.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$15.27M
Net income
-$14.33M
EBIT
-$15.19M
EBITDA
-$14.74M
Free cash flow
-$12.92M
Per share
EPS
-$0.66
EPS diluted
-$0.66
Free cash flow per share
-$0.54
Book value per share
$0.87
Revenue per share
$0
TBVPS
$1.01
Balance sheet
Total assets
$24.04M
Total liabilities
$3.41M
Debt
$0
Equity
$20.63M
Working capital
$19.5M
Liquidity
Debt to equity
0
Current ratio
7.2
Quick ratio
6.54
Net debt/EBITDA
1.39
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-50.5%
Return on equity
-57.7%
Return on invested capital
-956.5%
Return on capital employed
-72.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENLV stock price

How has the Enlivex Therapeutics stock price performed over time
Intraday
-1.1%
1 week
-2.11%
1 month
-10.58%
1 year
-31.11%
YTD
-20.51%
QTD
-4.14%

Financial performance

How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.27M
Net income
-$14.33M
Gross margin
N/A
Net margin
N/A
Enlivex Therapeutics's net income has increased by 45% YoY and by 4.6% from the previous quarter
The company's operating income rose by 43% YoY and by 3.9% QoQ

Price vs fundamentals

How does ENLV's price correlate with its fundamentals

Growth

What is Enlivex Therapeutics's growth rate over time

Valuation

What is Enlivex Therapeutics stock price valuation
P/E
N/A
P/B
1.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enlivex Therapeutics's EPS has soared by 53% YoY and by 10% from the previous quarter
ENLV's P/B is 29% below its 5-year quarterly average of 1.5 and 2.7% below its last 4 quarters average of 1.1
ENLV's equity is down by 23% year-on-year and by 13% since the previous quarter

Efficiency

How efficient is Enlivex Therapeutics business performance
The ROIC has plunged by 51% from the previous quarter
Enlivex Therapeutics's ROE has increased by 22% YoY
Enlivex Therapeutics's ROA has increased by 18% YoY

Dividends

What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENLV.

Financial health

How did Enlivex Therapeutics financials performed over time
The total assets has declined by 23% year-on-year and by 13% since the previous quarter
The total liabilities has contracted by 19% YoY and by 17% from the previous quarter
ENLV's debt is 100% lower than its equity
ENLV's equity is down by 23% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.